Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0SGUGL)
| ADC Name |
Ispectamab debotansine
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
ispectamab debotansine; CC-99712
Click to Show/Hide
|
|||||
| Organization |
Sutro Biopharma (Originator) (No Rights);Celgene (Top20 MNC)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Ispectamab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
|
Antigen Info | ||||
| Payload Name |
SC347
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Cys-12 ADC linker
|
Linker Info | ||||
| Conjugate Type |
Non-natural Amino Acids
|
|||||
| Combination Type |
debotansine
|
|||||
| Special Approval(s) |
Orphan drug (FDA)
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants must be ≥18 with measurable relapsed/refractory MM and ECOG 0-1, excluding those with CNS involvement, recent transplants (auto≤3mo/allo≤6mo), active HBV/HCV/HIV, pregnancy/lactation, or GVHD immunosuppression, with additional protocol-specified criteria applying.
|
||||
| Administration Dosage |
CC-99712 will be administered via intravenous (IV) infusion.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04036461 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | ||||
| Primary Endpoint |
The trial evaluates safety through adverse event monitoring (42+ days post-treatment), determines Maximum Tolerated Dose (≤33% DLT rate in first cycle), and assesses Dose Limiting Toxicities within 28 days in relapsed/refractory multiple myeloma patients.
|
||||
| Other Endpoint |
Key efficacy endpoints include IMWG-defined Overall Response Rate, Time to Response, Duration of Response, Progression-Free Survival, and Overall Survival (all tracked up to 3 years). Pharmacokinetic parameters (Cmax, Tmax, AUC, CLT, Ctrough) and anti-drug antibody development are also evaluated throughout the 3-year study period.
|
||||
References